SpringWorks Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q4 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
SpringWorks Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q4 2017 to Q2 2024.
  • SpringWorks Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$39.9M, a 48.8% increase year-over-year.
  • SpringWorks Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$301M, a 1.06% decline year-over-year.
  • SpringWorks Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$325M, a 17.2% decline from 2022.
  • SpringWorks Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$277M, a 59.5% decline from 2021.
  • SpringWorks Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$174M, a 282% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$301M -$39.9M +$38M +48.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 -$339M -$87.4M -$14M -19% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 -$325M -$94.3M -$20.1M -27.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 -$305M -$79.4M -$7.05M -9.74% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 -$298M -$77.9M -$8.88M -12.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$289M -$73.4M -$11.6M -18.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 -$277M -$74.2M -$18.1M -32.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 -$259M -$72.4M -$31.3M -76.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$228M -$69.1M -$22M -46.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 -$206M -$61.8M -$32M -107% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 -$174M -$56.1M -$67.3M -597% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 -$107M -$41M -$19.4M -89.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$87.2M -$47M -$27.1M -136% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$60.1M -$29.8M -$14.5M -94.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$45.6M $11.3M +$27.5M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 -$73.1M -$21.7M -$4.83M -28.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$68.2M -$19.9M -$6.05M -43.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 -$62.2M -$15.3M -$3.89M -34.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 -$58.3M -$16.2M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 -$16.8M -$11.8M -236% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$13.8M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-12
Q1 2019 -$11.4M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q3 2018 -$5M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q4 2017 -$4.64M Aug 19, 2017 Dec 31, 2017 10-K 2020-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.